ACVR2A and obesity disorder: It has been shown that pharmacological blockade of the activin A signalling pathway by using soluble activin type II receptors (ligand level), or antibody to ActRII (receptor level) increases muscle and bone mass, correct anaemia or protect against diet-induced obesity [28,29].